Lake Street Capital Begins Coverage on AbCellera Biologics (NASDAQ:ABCL)

Investment analysts at Lake Street Capital started coverage on shares of AbCellera Biologics (NASDAQ:ABCL – Get Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $19.00 price target on the stock. Lake Street Capital‘s target price would suggest a potential upside of 81.47% from the company’s previous close.

A number of other research analysts also recently commented on ABCL. Jefferies Financial Group reaffirmed a “buy” rating on shares of AbCellera Biologics in a research report on Monday. StoneX boosted their price target on shares of AbCellera Biologics from $11.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. JPMorgan Chase & Co. started coverage on shares of AbCellera Biologics in a research note on Tuesday, September 29th. They issued an “overweight” rating and a $17.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of AbCellera Biologics from $9.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Get Our Latest Stock Report on AbCellera Biologics

AbCellera Biologics Stock Down 5.0%

Shares of ABCL opened at $10.47 on Wednesday. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of -21.81 and a beta of 1.59. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $15.02. The stock has a 50 day moving average price of $12.32 and a 200 day moving average price of $7.37.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. The company had revenue of $10.64 million for the quarter, compared to analysts’ expectations of $8.42 million. AbCellera Biologics had a negative net margin of 218.54% and a negative return on equity of 15.35%. During the same quarter last year, the company earned ($0.19) earnings per share. On average, equities analysts anticipate that AbCellera Biologics will post -0.60 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Holdings Ltd. Thermopylae acquired 60,565 shares of AbCellera Biologics stock in a transaction on Thursday, November 12th. The stock was bought at an average price of $11.54 per share, for a total transaction of $698,920.10. Following the completion of the purchase, the insider owned 56,194,662 shares in the company, valued at $648,486,399.48. This represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in AbCellera Biologics during the second quarter worth $29,872,000. Bank of America Corp DE purchased a new position in AbCellera Biologics in the second quarter worth $48,211,000. Hsbc Holdings PLC acquired a new stake in AbCellera Biologics in the second quarter valued at $929,000. SEB Asset Management AB acquired a new stake in AbCellera Biologics in the first quarter valued at $1,188,000. Finally, WINTON GROUP Ltd purchased a new position in shares of AbCellera Biologics in the 2nd quarter valued at about $442,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

See Also

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.